Olaf Oberschmidt

Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved <i>Ex Vivo</i> Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells

Stephan Klöß, Olaf Oberschmidt, Michael Morgan et al. · Human Gene Therapy · 2017 · 134 citations

In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression

Axel-Rainer Hanauske, Ulrike Eismann, Olaf Oberschmidt et al. · Investigational New Drugs · 2007 · 85 citations

Tumor Heterogeneity, Medicine, Tumor Cells +9

Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering

Olaf Oberschmidt, Michael Morgan, Volker Huppert et al. · Human Gene Therapy Methods · 2019 · 66 citations · Full text

Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice

Philipp Beckhove, Olaf Oberschmidt, Axel R. Hanauske et al. · Anti-Cancer Drugs · 2007 · 54 citations

Tumor Biology, Breast Oncology, Oncology +15

Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer–Based “Off-the-Shelf” Acute Myeloid Leukemia Immunotherapies

Olaf Oberschmidt, Julia Dahlke, Xuan‐Khang Vu et al. · Human Gene Therapy · 2019 · 52 citations

Cell Therapy, Immunology, Nk Cells +17